Total U.S. pharmaceutical spending hit $805.9 billion in 2024, a 10.2% jump from the year before. But the story behind that number is more complicated than a simple price hike. Most of that growth came from people filling more prescriptions and from expensive new drugs entering the market, while average prices for existing drugs actually ticked down by 0.2%.
That single-year snapshot, though, masks a longer pattern of dramatic increases, particularly for brand-name and specialty medications. How much you personally feel those increases depends heavily on what type of drug you take, what kind of insurance you have, and how your pharmacy benefit is structured.
Specialty Drugs vs. Everything Else
The sharpest price increases over the past decade have been concentrated in specialty medications: drugs for conditions like cancer, autoimmune diseases, and rare genetic disorders. Between 2012 and 2021, total spending on specialty drugs in Medicare Part D rose by 566.5%, growing at a compound annual rate of 23.5%. The average cost per specialty prescription climbed 60.5% over that same period.
Traditional medications told a very different story. Total spending on non-specialty drugs actually fell by about 25% during those same years, largely because popular brand-name drugs lost patent protection and cheaper generics took their place. The average cost per non-specialty prescription rose just 10.4% across the entire decade, roughly 1% per year.
This split is the single most important thing to understand about drug pricing trends. If you take a generic blood pressure pill or cholesterol medication, your costs have been relatively stable. If you or a family member takes an injectable biologic for rheumatoid arthritis or a targeted cancer therapy, you’re in a completely different pricing universe.
How Drug Prices Compare to General Inflation
In the most recent data, prescription drug prices have actually risen more slowly than overall inflation. Between March 2023 and March 2024, prescription drug prices increased just 0.4%, while prices across the broader economy rose 3.5%. That gap is unusual. For much of the previous two decades, drug prices regularly outpaced general inflation.
Several forces are keeping a lid on prices right now. Generic competition continues to expand. Public and political pressure has made manufacturers more cautious about headline-grabbing price hikes. And new federal policy, particularly Medicare’s authority to negotiate prices directly, is beginning to change the calculus for drugmakers. But those forces apply unevenly. Hospital services, by comparison, jumped 7.7% in that same period, with outpatient care rising 8.3%.
The List Price Problem
One reason drug pricing is so confusing is that the price printed on the label often has little to do with what insurers, pharmacies, or even patients actually pay. Pharmacy benefit managers (PBMs), the companies that negotiate drug coverage on behalf of insurers, extract confidential rebates from manufacturers. The gap between a drug’s list price and the actual price after those rebates is known as the gross-to-net bubble, and it grew by more than 300% between 2012 and 2023.
This system creates a perverse incentive. Manufacturers raise list prices so they can offer larger rebates, which makes PBMs more likely to place their drug on a preferred formulary. PBMs, in turn, profit from retaining a portion of those rebates and from fees tied to the gross price. Higher list prices mean higher rebate potential, which means more revenue for PBMs. Research shows that every 1 percentage-point increase in the gross-to-net spread is associated with 0.35% higher list price inflation.
The people who get hurt are patients whose cost-sharing is based on the list price rather than the net price. If your copay is a percentage of a drug’s sticker price, you’re paying a share of an inflated number that doesn’t reflect what your insurer actually paid. This is why someone can be prescribed a drug that costs their insurance plan relatively little after rebates but still face a $200 copay at the pharmacy counter.
What Americans Actually Pay Out of Pocket
Per capita retail prescription drug spending rose from $974 in 2014 to $1,227 in 2022, an average increase of 3.8% per year. That figure includes both what insurers pay and what patients pay directly, but it captures the overall upward trajectory of drug costs in everyday life.
Cost is already causing people to skip medications. About 6.6% of privately insured adults who were prescribed medication reported not taking it as directed because of cost in 2021. That translates to millions of people rationing pills, splitting doses, or simply not filling prescriptions, decisions that can lead to hospitalizations and worse health outcomes down the road.
Medicare Drug Negotiation: Early Impact
For the first time, Medicare now has the authority to negotiate prices directly with manufacturers for certain high-cost drugs. The first round targeted 10 medications that together accounted for roughly $50.5 billion in Medicare Part D spending in a single year. The list includes some of the most widely used brand-name drugs in the country:
- Eliquis (blood clot prevention): $16.5 billion in gross costs, used by 3.7 million Medicare enrollees
- Jardiance (diabetes, heart failure): $7.1 billion, 1.6 million enrollees
- Xarelto (blood clot prevention): $6 billion, 1.3 million enrollees
- Januvia (diabetes): $4.1 billion, 869,000 enrollees
- Entresto (heart failure): $2.9 billion, 587,000 enrollees
- Enbrel (rheumatoid arthritis, psoriasis): $2.8 billion, 48,000 enrollees
- Imbruvica (blood cancers): $2.7 billion, 20,000 enrollees
- Stelara (psoriasis, Crohn’s disease): $2.6 billion, 22,000 enrollees
- Insulin products including NovoLog (diabetes): $2.6 billion, 777,000 enrollees
- Farxiga (diabetes, heart failure, chronic kidney disease): $3.3 billion, 799,000 enrollees
Negotiated prices for these drugs take effect in 2026. The scale of the discounts will determine whether the program meaningfully changes what patients pay at the pharmacy. Some of these drugs, like Enbrel and Imbruvica, are used by relatively few people but carry enormous per-patient costs. Others, like Eliquis, affect millions of patients and could produce widespread savings even with modest percentage reductions.
Where Prices Are Headed
The 2024 spending data reveals the current dynamic clearly: existing drug prices are roughly flat, but total spending keeps climbing because more people are taking medications and because newly launched drugs enter the market at high price points. Utilization alone drove a 7.9% increase in 2024 spending, while new drug launches added another 2.5%.
GLP-1 drugs for diabetes and weight loss are a major factor in rising utilization. So is the aging population and expanded use of specialty medications for conditions that previously had limited treatment options. Even if manufacturers hold list prices steady, total drug spending in the U.S. is projected to keep growing at a pace that puts pressure on insurers, employers, and patients. The price on any single pill may not be rising fast right now, but the total bill keeps getting larger.